Acute Coronary Syndromes, Ischemic Heart Disease
Conditions
Keywords
ischemic heart disease, acute coronary syndromes, percutaneous transluminal coronary angioplasty, platelet function, aspirin, clopidogrel, cilostazol
Brief summary
Effects of dual antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention has been proven. However, patients with low response to those agents are reported be associated with adverse clinical outcomes. We suppose that optimized antiplatelet therapy for individual patients based on platelet function assay may improve long-term outcomes especially in patients with high risk of thrombosis. In this prospective randomized study, patients in control group all receive standard dual antiplatelet therapy, and patients in optimized group receive different antiplatelet therapy according to risk stratification.
Interventions
DRUGcilostazol in addition to aspirin and clopidogrel
Sponsors
Shenyang Northern Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* non-ST-segment elevated acute coronary syndromes * patients undergoing selective or emergent PCI
Exclusion criteria
* administration of clopidogrel or ticlopidine within 2 weeks * ST-segment elevated myocardial infarction * contraindications of antiplatelet therapy * history of intracranial bleeding * known bleeding disorders * severe liver or kidney disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiac and cerebral events at 1 year | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Hemorrhage events at 1 year | 1 year |
Countries
China
Outcome results
None listed